Key statistics
On Monday, Shanghai Henlius Biotech Inc (2696:HKG.HS) closed at 68.90, -25.11% below its 52-week high of 92.00, set on Sep 09, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 71.05 |
|---|---|
| High | 72.70 |
| Low | 68.90 |
| Bid | 68.90 |
| Offer | 69.15 |
| Previous close | 70.35 |
| Average volume | 2.02m |
|---|---|
| Shares outstanding | 346.07m |
| Free float | 88.03m |
| P/E (TTM) | 40.95 |
| Market cap | 24.35bn HKD |
| EPS (TTM) | 1.72 HKD |
Data delayed at least 15 minutes, as of Feb 16 2026 02:37 GMT.
More ▼
Press releases
- Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan
- Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan
- Henlius Showcases "Globalisation 2.0" Strategy and Mid-to-Long-Term Innovation Blueprint at JPM 2026
- Henlius Showcases "Globalisation 2.0" Strategy and Mid-to-Long-Term Innovation Blueprint at JPM 2026
- Henlius CEO Dr. Jason Zhu to Deliver a Keynote Presentation at JPM 2026
- Henlius CEO Dr. Jason Zhu to Deliver a Keynote Presentation at JPM 2026
More ▼
